Investopedia: Can AngioDynamics Get Hearts Racing?

With another quarter in the books, it's becoming evident that there's no great recovery underway in patient visits to doctors. This first fiscal quarter was not a catastrophe for AngioDynamics (Nasdaq:ANGO) by any means, but nor was it a sign that business is getting back to the sort of growth trajectory that investors demand from small med-tech stocks. With a new CEO in place, a strong balance sheet, good technology in the clinic and a core market that should be bottoming out, patient value-oriented investors might want to check out this story.

For quite a while now, AngioDynamics' stock has suffered from the fact that core earnings growth has been about as exciting as a bucket of warm paste. This dearth of growth cost the prior CEO his job, and it is arguably the primary focus for the new man. Still, investors likely realize that "Rome wasn't built in a day" (though a lot of it did burn down in a single night ... ), and patience is the order of the day.

Read more at this link:
http://stocks.investopedia.com/stock-analysis/2011/Can-AngioDynamics-Get-Hearts-Racing-ANGO-COV-BCR-JNJ-ISRG-ICUI-EW-MMSI1011.aspx